| Molecular Formula | C19H15N3O2 |
| Molar Mass | 317.34 |
| Density | 1.37±0.1 g/cm3(Predicted) |
| Boling Point | 627.4±55.0 °C(Predicted) |
| Solubility | DMSO: ≥ 32 mg/mL |
| pKa | 7.79±0.60(Predicted) |
| Storage Condition | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| In vitro study | CP21R7 (Compound 9) is a selective inhibitor of GSK-3β, with an IC 50 of 1.8 nM; the IC 50 of CP21R7 against PKCα is 1900 nM. CP21R7 (CP21, 3 μM) potently activates canonical Wnt signaling with highest activity. CP21 significantly increases total levels of intracellular β-catenin. CP21 combined with BMP4 induces commitment of hPSCs towards mesoderm. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.151 ml | 15.756 ml | 31.512 ml |
| 5 mM | 0.63 ml | 3.151 ml | 6.302 ml |
| 10 mM | 0.315 ml | 1.576 ml | 3.151 ml |
| 5 mM | 0.063 ml | 0.315 ml | 0.63 ml |
| biological activity | CP21R7 (CP21) is a potent and selective inhibitor of GSK-3β, it can effectively activate the canonical Wnt signaling pathway. |
| Target | TargetValue GSK-3β (Cell-free assay) |
| Target | Value |
| in vitro study | CP21R7 (Compound 9) is a selective inhibitor of GSK-3β, with an IC 50 of 1.8 nM; the IC 50 of CP21R7 against PKC α is 1900 nM. CP21R7 (CP21, 3 μM) potently activates canonical Wnt signaling with highest activity. CP21 significantly increases total levels of intracellular β-catenin. CP21 combined with BMP4 induces commitment of hPSCs towards mesoderm. |